Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Hepatitis C: Consensus Outlook
    Learn More Hepatitis C: Consensus Outlook
    The worldwide hepatitis C (HCV) market is forecasted to grow to $17.7 billion in 2017.  The catalysts for this growth include a boost in diagnosis rates following an increase in screening, and the introduction more...
  • Colorectal Cancer: KOL Insight
    Learn More Colorectal Cancer: KOL Insight
    The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be...
  • Diabetes: Consensus Outlook
    Learn More Diabetes: Consensus Outlook
    Therapy Trends Consensus Outlook: Diabetes is an in-depth forecast report based on consensus figures from 13 leading analysts. Rich in tables and charts, the report maps the impact of future events to predict product and...
  • Diabetes: KOL Insight
    Learn More Diabetes: KOL Insight
    Therapy Trends KOL Insight: Diabetes analyses the current and predicted key issues, current products and late-stage pipeline product and gives you qualitative information based on exclusive interviews with 12 key...
  • Alzheimer’s disease: KOL Insight
    Learn More Alzheimer’s disease: KOL Insight
    In 2012, the Alzheimer’s disease (AD) market was dealt a huge blow following negative results from pivotal Phase III trials of Pfizer and J&J’s bapineuzumab and the intravenous formulation of the drug was...

customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved